Annovis Bio, Inc. ANVS
0.75 USD -0.09 (-11.01%)
Regular-session close
0.77 +0.03 +3.42%
After hours · Nov 19, 5:46 PM ET
0.7236 Day range 0.8293
0.62 52-week range 5.50
- YTD
- -78.37%
- 1 year
- -77.86%
News
benzinga.com Annovis Bio Receives Second Consecutive Positive Recommendation From Independent Data And Safety Monitoring Board For Its DUET-AD Phase 3 Trial In Early Alzheimer's Disease; Six-Month Topline Results On Track For March 2027 This 12-month review follows the DSMB’s positive 6-month feedback, which was announced in February 2026. The DSMB recommended that DUET-AD continue without modification, based on the data accumulated…
globenewswire.com Annovis Receives Second Positive DSMB Recommendation for its Phase 3 DUET-AD Study MALVERN, Pa., Nov. 17, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing buntanetap, an investigational…benzinga.com Roth Capital Reiterates Buy on Annovis Bio, Lowers Price Target to $3 Roth Capital analyst Boobalan Pachaiyappan reiterates Annovis Bio (NYSE:ANVS) with a Buy and lowers the price target from $7 to $3.
benzinga.com Annovis Bio Q3 EPS $(0.22) Beats $(0.32) Estimate Annovis Bio (NYSE:ANVS) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(0.32) by 31.25 percent. This is a 40.54 percent increase over losses of $(0.37)…
globenewswire.com Annovis Provides Corporate Updates and Reports Third Quarter 2026 Financial Results MALVERN, Pa., Nov. 13, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing buntanetap, an investigational…
globenewswire.com Annovis Bio Granted U.S. Patent Covering New Crystalline Form of Buntanetap U.S. Patent No. 12,780,831 covers posiphen (buntanetap) D-tartrate Form B, a highly crystalline dihydrate, together with pharmaceutical compositions and methods of preparation, providing protection…
globenewswire.com Annovis Announces Closing of $21.0 Million Public Offering with 24% Contribution from the Board Chairman Annovis Chairman of the Board invested $5.0 million as part of the underwritten public offering Company expects cash to fund operations through the pivotal Phase 3 Alzheimer's data readout in March…
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session Gainers Lakewood-Amedex (NASDAQ:LABT) shares moved upwards by 237.6% to $0.65 during Thursday's regular session. ADMA Biologics (NASDAQ:ADMA) stock increased by 25.62% to $13.16. The market value of…
globenewswire.com Annovis Announces Pricing of $21.0 Million Public Offering MALVERN, Pa., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral…
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session Gainers ADMA Biologics (NASDAQ:ADMA) shares rose 19.6% to $12.53 during Thursday's pre-market session. The market value of their outstanding shares is at $2.3 billion. As per the news, the Q3…benzinga.com Annovis Bio Plans To Commence Common Stock Offering; Terms Undisclosed Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases…
globenewswire.com Annovis Announces Launch of Proposed Public Offering MALVERN, Pa., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral…benzinga.com Annovis Bio Obtains Noncompliance Notice From NYSE Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such…
globenewswire.com Annovis Bio, Inc. Receives Continued Listing Standard Notice from the NYSE MALVERN, Pa., Oct. 30, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral…
globenewswire.com Annovis to Participate in U.S. Biotech Day 2026 and Pharma Partnering Summit 2026 MALVERN, Pa., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral…
globenewswire.com Annovis to Attend the CTAD 2026 with Three Presentations MALVERN, Pa., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral…
globenewswire.com Annovis Announces Partnership with Weave Bio, AI Regulatory Platform, in Preparation of NDA for Buntanetap in Alzheimer's Disease MALVERN, Pa., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral…
zacks.com Annovis Bio (ANVS) Loses 26.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner Annovis Bio (ANVS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in…
marketbeat.com Annovis Bio Targets March 2027 Alzheimer's Readout, Prepares Rolling NDA Annovis Bio NYSE: ANVS said it expects to report top-line results from the six-month portion of its pivotal Phase III Alzheimer's disease trial in March 2027, while preparing a rolling new drug…
globenewswire.com Annovis to Host Corporate Update Webinar on September 2, 2026 MALVERN, Pa., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral…
globenewswire.com Annovis Provides Corporate Updates and Second Quarter 2026 Financial Results MALVERN, Pa., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral…
globenewswire.com Annovis Reaches Full Enrollment in Pivotal Phase 3 Trial of Buntanetap for Early Alzheimer's Disease Pivotal Phase 3 trial enrolls 850 patients, exceeding original projections Study completion on track: symptomatic data readout - Q1 2027, disease-modifying data readout - Q1 2028 Company positions…
globenewswire.com Annovis Appoints Cheng Fang, Ph.D., as Chief Scientific Officer MALVERN, Pa., July 01, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral…
globenewswire.com Annovis Bio Regains NYSE Listing Compliance MALVERN, Pa., May 26, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy,…
globenewswire.com Annovis Announces Pricing of $15.0 Million Public Offering of Common Stock and Accompanying Warrants MALVERN, Pa., May 20, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy,…
globenewswire.com Annovis Announces Launch of Proposed Public Offering of Common Stock and Accompanying Warrants MALVERN, Pa., May 19, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy,…
globenewswire.com Annovis Provides Corporate Updates and Reports First Quarter 2026 Financial Results Phase 3 AD trial: 85% of patients enrolled; full enrollment on track in summer 2026 PD open-label extension (OLE) study: 40% of patients enrolled; full enrollment on track in fourth quarter 2026 New…
